Crohn's Disease Treatment Market - Global Forecast, 2022 - 2028

Crohn's Disease Treatment Market - Global Forecast, 2022 - 2028

Report Description
Crohn’s disease is a form of chronic inflammatory bowel disease (IBD) that causes inflammation in the gastrointestinal tract. This inflammation can take place anywhere between the ileum of the small intestine to the colon of the large intestine. Common symptoms of Crohn’s disease from mild to severe intensity include abdominal pain, reduced appetite, fever, and frequent diarrhea. Rectal bleeding is encountered in few cases due to fissures from inflammation at anal canal. Factors responsible for causing Crohn’s disease include hereditary genes, autoimmune reaction that causes inflammatory condition, and environmental factors such as bacteria and virus. The disease majorly affects people falling between age group of 15-35 years and occurs in moth males and females.
Market Dynamics
The North America and Europe regions have high incidence of Crohn’s disease, which is expected to drive the growth of market. According to the journal of Gastroenterology’s on Inflammatory Bowel Disease (IBD) in 2021, around 1.6 million patient in the U.S were suffering from of IBD, out of which considerable section belongs to Crohn’s disease. Additionally, fast-track drug approval application of FDA pertaining to treatments for Crohn’s disease is also expected to foster the market in the forecast years. The pipeline drugs offering innovative treatment solutions expecting to receive marketing approvals are anticipated to propel the market growth. For instance, launch of interleukin (IL) inhibitor and anti-integrin therapy for Crohn’s disease, risankizumab, is in the Phase III clinical trials of FDA developed by AbbVie and is expected to complete its trials by January 2022. However, lack of awareness regarding available treatment options is expected to act as hindrance in the market growth.
Key features of the study:
This report provides in-depth analysis of Crohn’s disease treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global Crohn’s disease treatment market based on the following parameters – company overview, product description, key highlights, financial performance and strategies
Key companies covered as a part of this study includes AbbVie Inc., Janssen Biotech, Inc., Allergan Inc., Bayer AG, Bristol-Myers Squibb, Pfizer, Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Novartis International AG, Sanofi, and Takeda Pharmaceutical Company Limited.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, market expansion, and marketing tactics
The global Crohn’s disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Crohn’s disease treatment market
Detailed Segmentation:
Global Crohn’s Disease Treatment Market, By Drug Type:
Antibiotics
Amino Salicylates
Corticosteroids
Immunomodulators
Others
Global Crohn’s Disease Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
Global Crohn’s Disease Treatment Market, By Region:
North America
By Drug Type:
Antibiotics
Amino Salicylates
Corticosteroids
Immunomodulators
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
U.S.
Canada
Latin America
By Drug Type:
Antibiotics
Amino Salicylates
Corticosteroids
Immunomodulators
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type:
Antibiotics
Amino Salicylates
Corticosteroids
Immunomodulators
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type:
Antibiotics
Amino Salicylates
Corticosteroids
Immunomodulators
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type:
Antibiotics
Amino Salicylates
Corticosteroids
Immunomodulators
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Type:
Antibiotics
Amino Salicylates
Corticosteroids
Immunomodulators
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
South Africa
Central Africa
North Africa
Company Profiles
AbbVie, Inc. *
Company Overview
Product Portfolio
Key Highlights
Financial Performance
Strategies
Janssen Biotech, Inc.
Allergen, Inc.
Bayer AG
Bristol Myers Squibb
Boehringer Ingelheim GmbH
Pfizer, Inc.
F-Hoffmann La-Roche
Eli Lily and Company
GlaxoSmithKline Plc
Novartis AG
Sanofi
Takeda Pharmaceutical Company Limited
“*” marked represents similar segmentation in other categories in the respective section.